Evan Seigerman Recommends Buy on Amgen Due to Promising MariTide Trial Results and Strategic Growth Moves
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report) and keeping the price target at $362.00.Don't ...
Seeking Alpha11h
Amgen: Checks All The Wrong Boxes
In the case of Amgen (NASDAQ:AMGN), I can honestly say I knew very little about the stock beyond its name and sector for a ...
pharmaphorum10h
Amgen's big reveal of obesity data falls a bit flat
William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...
Amgen price target lowered to $330 from $360 at RBC Capital
RBC Capital analyst Gregory Renza lowered the firm’s price target on Amgen (AMGN) to $330 from $360 and keeps an Outperform rating on the ...
Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You
Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.
Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations
The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...
Wait for longer-term data with Amgen's GLP-1, says Piper Sandler's Christopher Raymond
Wait for longer-term data with Amgen's GLP-1, says Piper Sandler's Christopher Raymond ...
Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...